Finance Watch: Aiolos Launches With $245m Series A; OrbiMed’s New Funds Total $4.3bn
Big Rounds Dominate As Quarterly VC Totals Creep Higher
Private Company Edition: Quarter-over-quarter increases in venture capital have been bolstered by fewer but larger rounds, like the recent $245m series A for Aiolos. Also, OrbiMed raised $4.3bn across three new VC funds, Rampart completed an $85m series A and Atom Bioscience raised an $83m series D.
You may also be interested in...
VC data from Evaluate show quarter-over-quarter drops in the number of biopharma companies raising private cash and in the amount of money raised as investors ride out public market troubles.
The first $1bn quarter since 2021 suggests that biotech’s IPO window is opening once more. But times remain tough, and many recently listed groups have seen their valuations fall.
The biotech company already has a candidate with a tough target in the clinic for COVID-19 and plans to have four to six candidates in the clinic over the next two years following a $273m series C round.